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Abstract
Background: b-thymosins play roles in cytoskeleton rearrangement, angiogenesis, fibrosis and reparative process,
thus suggesting a possible involvement in the pathogenesis of systemic sclerosis. The aim of the study was to
investigate the presence of thymosins b4, b4 sulfoxide, and b10 in bronchoalveolar lavage fluid of scleroderma
patients with interstitial lung disease and the relation of these factors with pulmonary functional and radiological
parameters.
Methods: b-thymosins concentrations were determined by Reverse Phase-High Performance Liquid
Chromatography-Electrospray-Mass Spectrometry in the bronchoalveolar lavage fluid of 46 scleroderma patients
with lung involvement and of 15 controls.
Results: Thymosin b4, b4 sulfoxide, and b10 were detectable in bronchoalveolar lavage fluid of patients and
controls. Thymosin b4 levels were significantly higher in scleroderma patients than in controls. In addition,
analyzing the progression of scleroderma lung disease at one-year follow-up, we have found that higher thymosin
b4 levels seem to have a protective role against lung tissue damage. Thymosin b4 sulfoxide levels were higher in
the smokers and in the scleroderma patients with alveolitis.
Conclusions: We describe for the first time b-thymosins in bronchoalveolar lavage fluid and their possible
involvement in the pathogenesis of scleroderma lung disease. Thymosin b4 seems to have a protective role against
lung tissue damage, while its oxidation product mirrors an alveolar inflammatory status.
Background
b-thymosins are a family of G-actin sequestering pep-
tides involved in cytoskeleton rearrangement, intra-
cellular signaling, cell-cell adhesion, motility, survival,
differentiation, and malignant transformation [1]. While
in mammalian tissues thymosin b4 is usually the main
peptide, representing about 70-80% of the total b-thymosins
content [2], thymosin b10 is usually detectable at concen-
trations about 5-10-fold lower compared to thymosin b4.
However, in preneoplastic and neoplastic tissues and in
activated lymphocytes the ratio thymosin b10/b4 seems to
increase [3,4]. The oxidation product of thymosin b4 at
the Methionine6 residue, thymosin b4 sulfoxide, was also
detectable in many body fluids [5].
Although the secretion pathway is not fully under-
stood, recent studies highlighted various extra-cellular
roles for these peptides [1]. Thymosin b4 is essential for
platelet-clot formation and wound healing [6]. More-
over, while thymosin b10 seems to have anti-angiogenic
properties, significantly decreasing mRNA levels of vas-
cular endothelial growth factor (VEGF) and of VEGF
receptor-1, thymosin b4 promotes angiogenesis [7,8]. Of
interest thymosin b4 can up-regulate the expression of
hepatocyte growth factor and down-regulate the expres-
sion of platelet derived growth factor-beta receptor in a
model of liver fibrosis, thus suggesting an anti-fibrotic
potential role of thymosin b4 [9]. Furthermore, both thy-
mosin b4 and thymosin b4 sulfoxide seem to have anti-
inflammatory properties [10,11].
T h er o l eo fb-thymosins in cytoskeleton rearrange-
ment, angiogenesis, fibrosis and reparative process
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pathogenesis of systemic sclerosis, a multi-organ con-
nective tissue disease characterized by skin and internal
organ fibrosis and microvascular abnormalities. The
cytokines and paracrine factors underlying fibrosis and
vasculopathy in scleroderma are not completely charac-
terized yet.
T h ep r e s e n c eo ft h y m o s i nb4 and thymosin b10 in
body fluids, such as saliva, has been recently demon-
strated using a number of immunological [12] and pro-
teomic [5] techniques, but not in bronchoalveolar lavage
fluid (BALF). Therefore, the present study has been car-
ried out with the aim to demonstrate the presence of
b-thymosins in BALF of normal subjects and of sclero-
derma patients with interstitial lung disease and to
correlate their levels with the biologic, functional and
radiological parameters of lung involvement, through
Reverse Phase-High Performance Liquid Chromatogra-
phy-Electrospray-Mass Spectrometry analysis (RP-
HPLC-ESI-MS) of the naturally occurring peptides.
I nt h i ss t u d yw eh a v ed e s c r i b e df o rt h ef i r s tt i m e
b-thymosins in human BALF. Moreover, we have
hypothesized a possible involvement of these factors in
the pathogenesis of scleroderma lung disease. In fact, we
have found higher concentrations of thymosin b4i nt h e
BALF of scleroderma patients with lung involvement
compared to the normal counterpart and of thymosin
b4 sulfoxide in the subset of scleroderma patients with
alveolitis. In addition, analyzing the progression of scler-
oderma lung disease at one-year follow-up, we have
found that higher thymosin b4 levels seem to have a
protective role against lung tissue damage.
Methods
Scleroderma patients
46 scleroderma patients with evidence of interstitial lung
disease on high resolution computed tomography
(HRCT) (reticular pattern and/or ground glass or hon-
eycombing), consecutively admitted to the outpatient
clinic of the Rheumatology Division of the Catholic
University in Rome from January 2007 to December
2009, consenting to undergo bronchoalveolar lavage,
have been included in the study. All the patients have
fulfilled the criteria proposed by the American College
of Rheumatology [13] and have been classified in limited
and diffuse subset according to LeRoy classification [14].
ANA (antinuclear antibodies) have been determined by
indirect immunofluorescence using Hep 2 cells as sub-
strates and autoantibody specificities were assessed by
enzyme-linked immunosorbent assay (ELISA) [15].
Demographic, clinical and lung involvement characteris-
tics of the patients are summarized in the table 1.
The study is conform to the recommendations of the
Declaration of Helsinki and the study protocol has been
approved by the local ethical committee. An informed
written consent has been obtained from the patients.
Control subjects
As controls we have used the BALF from 15 subjects
who performed the exam for a solitary pulmonary
nodule, either in the lobe with the nodule or in the con-
tro-lateral normal lobe, after obtaining an informed
written consent. BALF cytological and microbiological
exams have been all negative. Controls’ mean age has
been 60.0 ± 12.0 years, females have been 9 (60.0%),
smokers have been 3 (20.0%).
Study design
We have investigated through RP-HPLC-ESI-MS the
presence of b-thymosins in the BALF of 46 scleroderma
patients with interstitial lung disease and 15 normal
subjects, and we have studied the correlations between
BALF b-thymosin levels and the biologic, functional and
radiological parameters of scleroderma lung involvement
and of its progression. All the enrolled patients have
performed pulmonary function tests, echocardiography,
HRCT of the lung within one month before performing
bronchoalveolar lavage. Pulmonary function tests and
HRCT have been repeated after a one-year follow-up.
Pulmonary function tests
Pulmonary function tests have been performed to define
forced vital capacity (FVC) and carbon monoxide diffus-
ing capacity (DLCO), as described elsewhere [16,17].
FVC <80% with normal forced expiratory volume in one
second/FVC has been defined as restrictive lung disease
[16]. A decrease in FVC >10% and in DLCO >15% at
one-year follow-up has been considered a clinically sig-
nificant variation [18,19].
Echocardiography
Pulmonary artery systolic pressure has been calculated
with the simplified Bernoulli equation [15]. High pul-
monary arterial pressure (HPAP) has been defined as
pulmonary artery systolic pressure >35 mmHg [20].
HRCT score system
HRCT has been performed as described elsewhere [15].
Two independent readers have scored ground glass opa-
city (alveolar score) and honeycombing (honeycombing
score) on a scale of 0-5 in the three lobes of both lungs,
as described elsewhere [15]. An increase in alveolar or
honeycombing score >1 point at one-year follow-up has
been considered clinically significant.
Bronchoalveolar lavage analysis
Bronchoalveolar lavage has been performed as reported
elsewhere [15]. Four 60 mL aliquots of saline solution
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112.4 ± 30.3 mL in the patients with alveolitis, 129.6 ±
25.7 mL in the patients without alveolitis, and 100.4 ±
28.4 mL in control subjects. The percentages of alveolar
macrophages, lymphocytes, neutrophils and eosinophils
have been recorded. Cells with the forward and side scat-
ter properties of lymphocytes have been analyzed on a
flow cytometer (Beckman Coulter, EXPO32). Used anti-
bodies included Phycoerythrincyanin(PC5)-conjugated
anti-CD3 monoclonal antibodies (mAb), Phycoerythrin
Texas red(ECD)-conjugated anti-CD4 mAb, fluorescein
isothiocyanate(FITC)-conjugated anti-CD8 mAb, Phy-
coerythrin(PE)-conjugated anti-CD19 mAb, (all from
Beckman Coulter, Marseille, France). Alveolitis has been
diagnosed when the percentage of neutrophils was
33%
and/or eosinophils
32% [21].
Among the patients with alveolitis, 5 received azathiopr-
ine 100 mg/die per os for 12 months, and 7 received cyclo-
phosphamide 100 mg/die per os for 8.6 weeks (6 g) then
followed by azathioprine as above, 12 received only con-
ventional therapies [15].
BALF collection and preparation for RP-HPLC-ESI-MS
analysis
Immediately after collectiona na c i d i cs o l u t i o no f0 . 2 %
aqueous trifluoroacetic acid has been added in ice bath to
5 mL BALF in 1:1 v:v ratio, and the solution has been
centrifuged at 10,000 g for 10 min. The supernatant has
been separated from the precipitate. The acid clear speci-
men has been freeze-dried, dissolved in 1 mL of 0,2%
aqueous trifluoroacetic acid solution and 100 ul aliquots
of the solution directly injected into the RP-HPLC-MS
apparatus. The remaining acidic solution has been stored
to -80°C for further analysis.
RP-HPLC-ESI-MS analysis
All HPLC-MS reagents have been of analytical grade and
have been purchased from Farmitalia Carlo Erba (Milan,
Italy), Merck (Damstadt, Germany), and Sigma-Aldrich
(St. Louis, MI, USA). Standards of b-thymosins have
been purchased from Bachem (Bubendorf, Switzerland).
The HPLC-ESI-IT-MS apparatus has been a Surveyor
HPLC system (Thermo Fisher, San Jose, CA, USA) con-
nected by a T splitter to a photo diode-array detector
and to an LCQ Deca-XP Plus mass spectrometer. The
chromatographic column has been a 150 × 2.1 mm
Vydac (Hesperia, CA, USA) C8 column, with 5 μm parti-
cle diameter. The eluents have been (A) 0.056% aqueous
TFA and (B) 0.050% TFA in ACN/water 80:20 v/v. The
applied gradient has been linear from 0 to 55% of (B) in
40 min, at a flow rate of 0.30 mL/min. The T splitter has
addressed 0.20 mL/min toward the diode-array detector
and 0.10 mL/min toward the ESI source. The diode array
detector has been set at 214 and 276 nm. Mass spectra
Table 1 Demographic, clinical and lung involvement characteristics of 46 scleroderma patients
All scleroderma Patients 24 scleroderma pts with alveolitis 22 scleroderma pts without alveolitis
Age (y, mean ± SD) 55.1 ± 14 60.6 ± 11.7* 49 ± 14
Disease duration (y, mean ± SD)** 6.1 ± 6.2 5.4 ± 5.4 6.9 ± 7.1
Early disease (<3 y) n (%) 21 (45.6%) 12 (50%) 9 (40.9%)
Female n (%) 36 (78.3%) 20 (83.3%) 16 (72.7%)
dSSc n (%) 15 (32.6%) 7 (29.2%) 8 (36.4%)
AntiScl70 n (%) 28 (60.9%) 16 (66.7%) 12 (54.5%)
Anticentromere n (%) 5 (10.9%) 2 (8.3%) 3 (12.6%)
Antiribonucleoprotein n (%) 3 (6.5%) 1 (4.2%) 2 (9.1%)
Antinucleolus n (%) 3 (6.5%) 2 (8.3%) 1 (4.5%)
FVC% (mean ± SD) 93.1 ± 20.9 89.2 ± 23.1 97.3 ± 17.8
DLCO% (mean ± SD) 52.3 ± 14.8 48.9 ± 17.1 56 ± 11.2
Restrictive lung disease n (%) 14 (30.4%) 11 (45.8%)* 3 (13.6%)
Ground glass score (mean ± SD) 7.8 ± 5.6 9.7 ± 5.8* 5.6 ± 4.6
Interstitial score (mean ± SD) 6.3 ± 2.7 6.6 ± 2.8 5.9 ± 2.6
Alveolitis on BALF 24 (52.2%) / /
PASP (mmHg; mean ± SD) 27.8 ± 5.7 30.8 ± 5.7* 25.1 ± 4.2
HPAP n (%) 5 (10.9%) 5 (20.8%)* 0
Treatment n (%) 12 (26.1%) 12 (50.0%) 0
Smokers n (%) 6 (13%) 4 (16.7%) 2 (9.1%)
pts: patients; y: years; SD: standard deviation; n: number; dSSc: diffuse disease; FVC: forced vital capacity; DLCO: carbon monoxide diffusing capacity; BALF:
bronchoalveolar lavage fluid; PASP: pulmonary arterial systolic pressure; HPAP: high pulmonary arterial pressure;
*p < 0.05: pts with alveolitis versus pts without alveolitis.
** first SSc sign other than Raynaud’s phenomenon.
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spray voltage has been 4.50 kV and the capillary tempera-
ture 220°C.
Some samples of BALF have been also analyzed by an
Ultimate 3000 Nano/Micro-HPLC apparatus (Dionex,
Sunnyvale, CA, USA) equipped with an FLM-3000-Flow
manager module coupled to an LTQ Orbitrap XL appara-
tus (Thermo Fisher). The column has been a Biobasic 8
capillary column with 3 lm particle diameter (column
dimension 180 lm id610 cm). The chromatographic elu-
ents have been (A) 0.1% aqueous formic acid and (B) 0.1%
formic acid in ACN. The applied gradient has been 0-4
min 5% B, 4-38 min from 5 to 50% B (linear), 38-41 min
from 50 to 90% B (linear), at a flow rate of 4 μL/min. Mass
spectra have been collected in full scan (MS data) and also
in data-dependent scan (MS/MS data) mode with a capil-
lary temperature of 250°C, a sheath gas flow of 17 arbitrary
unities, a source voltage of 3.6 kV, and a capillary voltage
of 32 V. Measurements have been performed in the posi-
tive ion mode and mass accuracy has been calibrated
before measurements. Selected protein charge states have
been isolated with a width of m/z 6-10 and activated for
30 ms using 30% normalized collision energy and an acti-
vation q of 0.25.
Identification and quantification of ß-thymosins
b-thymosins have been identified in the HPLC-ESI pat-
tern by comparison with peptide standards. Sequences
of thymosin b4 and thymosin b10 have been also con-
firmed by high resolution dynamic MS/MS experiments
performed by the LTQ Orbitrap XL apparatus on a
BALF sample using the conditions described in the pre-
vious section and obtaining fragmentations comparable
to that previously reported for the identification of thy-
mosin b4 and thymosin b10 in human saliva [5].
Satisfactory linear correlation has been found between
t h ea b s o l u t eq u a n t i t yo ft h y m o s i nb4 and thymosin b10
peptide standards and the extracted ion current peak
area (R = 0.999; coefficient 2.16 × 10
6 extracted ion cur-
rent peak area per picomole of peptide). Thus, the
extracted ion current peak area has been used to calcu-
late concentrations, taking into account the correlation
coefficient and the injected sample volume. The latter
has corresponded to 100 μl in experiments performed on
10 times concentrated BALF. The extracted ion current
peaks have been revealed by selecting the following ions:
thymosin b4, [M+5H]5+ = 993.8 m/z, [M+4H]4+ =
1241.9 m/z, [M+3H]3+ = 1655.5 m/z; thymosin b4s u l f -
oxide [M+5H]5+ = 996.9 m/z, [M + 4H]4+ = 1245.9 m/z,
[M + 3H]3+ = 1660.8 m/z; thymosin b10, [M + 5H]5+=
988.3 m/z, [M+4H]4+ = 1235.1 m/z, [M+3H]3+ = 1646.5
m/z. Windows for all these values have been ± 0.5 m/z.
The percentage error of the measurements has been less
than 10%.
Data analysis
Deconvolution of averaged ESI mass spectra has been
automatically performed either by the software provided
with the Deca-XP instrument (Bioworks Browser) or by
MagTran 1.0 software (Zhang and Marshall, 1998).
Experimental mass values have been compared with aver-
age theoretical values available at the Swiss-Prot data
bank (http://us.expasy.org/tools), where thymosin b4 and
thymosin b10 have the codes P62328 and P63313, respec-
tively. Deconvolutions of Orbitrap MS/MS data have
been performed using the software provided with the
LTQ Orbitrap XL (Xctract on QualBrowser 2.0).
Statistical analysis
Data have been analyzed using SPSS 12.0 (SPSS.
Chicago. IL-USA). Categorical variables have been ana-
lyzed using c
2 test or Fisher’s test, depending on sample
size restrictions and the Odds’ Ratio (OR) with 95%
confidence interval (CI95%) have been calculated.
Mann-Whitney’s or Wilcoxon’s rank sum test, as appro-
priate, have been used to compare continuous variable.
Spearman’s rank correlation have been used to evaluate
the relationship between different disease parameters.
A value of p <0.05 has been considered statistically
significant.
Results
b-thymosins in the BALF of scleroderma patients and
controls
Considering the total b-thymosin content, the percen-
tages of thymosin b4, b4 sulfoxide and b10 have been
similar in patients and controls (82.4%, 4.3%, 13.3% ver-
sus 82.4%, 5.0%, 12.6%, respectively).
Thymosin b4 has been consistently detected in all the
BALF of both patients and controls. Thymosin b4 sulf-
oxide was detected in 14 (30%) of the scleroderma
patients and in 5 (33.3%) of the controls and thymosin
b10 in 28 (60.9%) of the scleroderma patients and in 8
(53.3%) of the controls (p = ns) (Table 2).
Thymosin b4 concentration has been significantly
higher in the BALF of the scleroderma patients than in
the controls (0.310 ± 0.372 μmol/L versus 0.112 ± 0.084
μmol/L, respectively; p = 0.008) (Table 2 and figure 1).
Thymosin b4 sulfoxide and thymosin b10 levels have
been also found to be higher in the BALF of the sclero-
derma patients compared to the controls, yet the differ-
ences have been not significant (Table 2 and figure 1).
Among the control subjects, higher thymosin b4 and
b4 s u l f o x i d el e v e l sh a v eb e e nf o u n di nt h eB A L Fo ft h e
smokers (0.238 ± 0.037 and 0.023 ± 0.011 μmol/L versus
0.08 ± 0.058 and 0.003 ± 0.007 μmol/L; p = 0.014 and
p = 0.006, respectively). Thymosin b4 sulfoxide has been
detected in the BALF of 3/3 smoking control subjects
and in 2/6 scleroderma smoking patients.
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alveolitis and without alveolitis
Among the scleroderma patients, thymosin b4 sulfoxide
has been detected in 10 (41.6%) of the patients with alveo-
litis versus 4 (18.1%) of the patients without alveolitis
(p = ns) (Table 3). Thymosin b10 has been detected in
13 (54.2%) of the patients with alveolitis versus 15 (68.2%)
of the patients without alveolitis (p = ns) (Table 3).
In addition, thymosin b4 sulfoxide levels has been sig-
nificantly higher and thymosin b4/b4 sulfoxide ratio has
been significantly lower in the scleroderma patients with
alveolitis compared to the patients without alveolitis
(0.025 ± 0.052 and 7.3 ± 4.6 μmol/L versus 0.006 ± 0.02
and 14.6 ± 4.9 μmol/L; p = 0.052 and p = 0.024, respec-
tively) (Table 3 and figure 1). Although thymosin b4 and
thymosin b10 levels have been higher in the BALF of
scleroderma patients with alveolitis compared to the
patients without alveolitis, the differences have been not
significant (Table 3 and figure 1). No correlations have
been found between thymosin b10/b4 ratio and any lung
involvement indices.
Correlation between BALF b-thymosin levels and BALF
cytology
A significant, even if weak, correlation has been found
between thymosin b4 sulfoxide levels and BALF neutrophil
percentage count (p = 0.010; r = +0.36) (Figure 2). More-
over, thymosin b4 sulfoxide levels have inversely correlated
with BALF CD4/CD8 ratio (p = 0.007; r = -0.40) (Figure 2)
and CD4 percentage count (p = 0.036; r = -0.32) and
directly with CD8 percentage count (p = 0.016; r = +0.36).
Thymosin b10 levels have directly correlated with
BALF CD3 (p = 0.035; r = +0.31) and CD4 percentage
count (p = 0.039; r = +0.31) (Figure 2).
Correlation between BALF b-thymosin levels and lung
involvement parameters
The scleroderma patients with restrictive lung disease
have had higher thymosin b4 sulfoxide levels (0.034 ±
0.065 μmol/L versus 0.008 ± 0.022 μmol/L; p = 0.042).
This data has associated with the significantly higher
frequency of restrictive lung disease in the patients with
alveolitis. Thymosin b10 levels have inversely with
DLCO (p = 0.009; r = -0.38) (Figure 2).
The scleroderma patients experiencing a significant
alveolar score worsening on high resolution computed
tomography after one-year follow-up have had lower
Table 2 Concentration and frequency of b-thymosins in
scleroderma patients and controls
46 scleroderma pts 15 controls
presence of Tb4, n pts (%) 46 (100%) 15 (100%)
Tb4 (μmol/L, mean ± SD) 0.310 ± 0.372* 0.112 ± 0.084
(median, range) (0.21, 0-2.1) (0.09, 0-0.26)
presence of sTb4, n pts (%) 14 (30%) 5 (33%)
sTb4 (μmol/L, mean ± SD) 0.016 ± 0.041 0.007 ± 0.011
(median, range) (0,0-0.24) (0.01, 0-0.08)
presence of Tb10, n pts (%) 28 (60.9%) 8 (53.3%)
Tb10 (μmol/L, mean ± SD) 0.050 ± 0.072 0.017 ± 0.022
(median, range) (0.02, 0-0.3) (0, 0-0.04)
Tb4/sTb4 ratio (mean ± SD) 9.4 ± 2.6 11.0 ± 4.6
Tb4: thymosin b4; n: number; pts: patients; SD: standard deviation; sTb4:
thymosin b4 sulfoxide; Tb10: thymosin b10.
*p < 0.05: pts versus controls.
Tbeta4
controls
no alveolitis
alveolitis
0.0
0.1
0.2
0.3
0.4
0.5
1.0
1.5
2.0
2.5
T
b
e
t
a
4
 
l
e
v
e
l
s
 
u
m
o
l
/
m
l
sTbeta4
controls
no alveolitis
alveolitis
0.00
0.01
0.02
0.03
0.2
0.4
s
T
b
e
t
a
4
 
l
e
v
e
l
s
 
u
m
o
l
/
L
Tbeta10
controls
no alveolitis
alveolitis
0.00
0.01
0.02
0.03
0.04
0.05
0.1
0.2
0.3
0.4
T
b
e
t
a
1
0
 
l
e
v
e
l
s
 
u
m
o
l
/
L
p=0.05
Tbeta4
controls
no alveolitis
alveolitis
0.0
0.1
0.2
0.3
0.4
0.5
1.0
1.5
2.0
2.5
T
b
e
t
a
4
 
l
e
v
e
l
s
 
u
m
o
l
/
m
l
sTbeta4
controls
no alveolitis
alveolitis
0.00
0.01
0.02
0.03
0.2
0.4
s
T
b
e
t
a
4
 
l
e
v
e
l
s
 
u
m
o
l
/
L
Tbeta10
controls
no alveolitis
alveolitis
0.00
0.01
0.02
0.03
0.04
0.05
0.1
0.2
0.3
0.4
T
b
e
t
a
1
0
 
l
e
v
e
l
s
 
u
m
o
l
/
L
p=0.05 p=0.05
BALF: bronchoalveolar lavage fluids; T: thymosin; s: sulfoxide      
Figure 1 BALF b-thymosins concentrations in scleroderma patients with and without alveolitis and in controls.
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Page 5 of 8BALF thymosin b4 levels (0.214 ± 0.290 versus 0.386 ±
0.457 μmol/L, respectively; p = 0.034). There have been
no correlations between b-thymosin levels and pulmon-
ary function test decline. There were no differences
between treated and untreated patients.
Discussion
In this study we have described for the first time the pre-
sence of b-thymosins in human BALF. The BALF relative
proportions of thymosin b4 (about 85%), b4 sulfoxide
(about 5%) and b10 (about 10%) have been similar to
those reported in other biological fluids and in the intra-
cellular compartment [2,5]. However, thymosin b4 con-
centration in BALF (0.1 μM) was about 10-fold higher
than that reported in the plasma (10 nM) [22,23].
Although the mechanism of thymosin b4 extra-cellular
release is not known, it seems that thymosin b4 might
escape from damaged cells because of its small size [23].
Then, considering that pulmonary epithelial cells and
alveolar macrophages are constantly exposed to environ-
mental toxicants, it can be hypothesized a passive cellular
release of thymosin b4 rather than an active compartmen-
talization of thymosin b4 in the lung where it would exert
a cyto-protective effect. In this context it could be
explained the higher BALF thymosin b4 levels founded in
smokers and in a pathological condition such as sclero-
derma interstitial lung disease. Interestingly, the sclero-
derma patients experiencing a worsening in the alveolar
score had relatively lower BALF thymosin b4 levels. This
data could support the role of thymosin b4 in tissue
repairing as already reported in other conditions as
wound healing [6], ischemic heart disease [24], and cor-
nea lesions [25]. These data are consistent with the ability
of thymosin b4 to down-regulate a number of key inflam-
matory cytokines like tumor necrosis factor-a [9].
Our study suggests but does not clarify the possible
involvement of b-thymosins in scleroderma lung disease;
however, considering the significant difference (about 3
folds) in thymosin b4 levels in the BALF of scleroderma
patients compared to normal counterpart, thymosin b4
could be considered a biomarker of lung involvement in
systemic sclerosis. This seems to be particularly interest-
ing in the light of a recent peptidomic study reporting
that plasma thymosin b4 is a biomarker of rheumatoid
arthritis, another rheumatologic disease with lung invol-
vement [26]. In parallel, thymosin b4 sulfoxide could be
considered a biomarker of lung oxidative stress. In fact,
the higher levels of thymosin b4 sulfoxide found in
smoking control subjects could mirror the oxidative
stress status. Methionine residues are somewhat sensi-
tive to oxidation, and many proteins can be inactivated
through this mechanism. In smokers, methionine oxida-
tion is essential for a(1)-antitrypsin inactivation and
pathologic lung remodeling [27]. Indeed, thymosin b4
oxidation could actually represent a scavenger mechan-
ism, able to reduce the negative effects of oxidative
stress on other lung proteins and enzymes. It has been
reported that scleroderma patients with alveolitis had a
more extensive interstitial lung disease, a higher risk to
worsen and a poor prognosis [28]. All pulmonary dis-
eases with an inflammatory component, like alveolitis,
have also a component of oxidative stress. This explains
the higher thymosin b4 sulfoxide levels in the subgroup
of scleroderma patients with alveolitis and the positive
correlation between thymosin b4 sulfoxide and both
BALF neutrophil percentage count and CD8 cells. BALF
CD8 cells are, in fact, associated with the production of
T-helper 2 cytokines and the decline of pulmonary func-
tion in scleroderma patients [29].
Although many studies on thymosin b10 have been
reported, its functions and molecular mechanisms in
human diseases are largely unknown. Even if thymosin
b4 and b10 have identical actin-binding sites, they have
different extracellular activity and different expression
pattern during embryological development or in cancer.
Our data show that thymosin b4 and b10 h a v eas i m i l a r
expression pattern in scleroderma interstitial lung dis-
ease, maybe due to a passive release from damaged cells.
The relationship between thymosin b10 and BALF lym-
phocyte percentage count indicates that thymosin b10
could be released by infiltrated and activated BALF lym-
phocytes [3]. The negative correlation between thymosin
b10 and DLCO suggests a potential inhibiting role of
thymosin b10 on alveolar-capillary permeability. Recently
a positive correlation between BALF VEGF and DLCO
Table 3 Concentration and frequency of b-thymosins in
scleroderma patients with or without alveolitis
24 scleroderma pts
with alveolitis
22 scleroderma pts
without alveolitis
presence of Tb4,
n pts (%)
24 (100%) 22 (100%)
Tb4 (μmol/L,
mean ± SD)
0.356 ± 0.464 0.256 ± 0.236
(median, range) (0.21, 0-2.1) (0.13, 0-1.0)
presence of sTb4,
n pts (%)
10 (41.6%) 4 (18.1%)
sTb4 (μmol/L,
mean ± SD)
0.025 ± 0.052* 0.006 ± 0.219
(median, range) (0, 0-0.24) (0, 0-0.1)
presence of Tb10,
n pts (%)
13 (54.2%) 15 (68.2%)
Tb10 (μmol/L,
mean ± SD)
0.059 ± 0.088 0.040 ± 0.049
(median, range) (0.01, 0-0.3) (0.02, 0-0.17)
Tb4/sTb4 ratio
(mean ± SD)
7.328 ± 4.626 * 14.582 ± 4.907
Tb4: thymosin b4; n: number; pts: patients; SD: standard deviation; sTb4:
thymosin b4 sulfoxide; Tb10: thymosin b10.
*p < 0.05: pts versus controls.
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genetic effect of thymosin b10 and the main role of
VEGF in the regulation of lung permeability, it will be
interesting to investigate t h ep o s s i b l er e l a t i o n s h i p
between thymosin b10 and VEGF in the lung.
Conclusions
In this study we have described for the first time the pre-
sence of b-thymosins in human BALF with a concentra-
tion about 10-fold higher than that reported in the
plasma. Moreover, we found higher concentrations of
thymosin b4 in the BALF of scleroderma patients with
lung involvement compared to the normal counterpart
and of thymosin b4 sulfoxide in the subset of sclero-
derma patients with alveolitis, thus suggesting a possible
role of these paracrine factors in systemic sclerosis as bio-
markers of interstitial lung disease and alveolitis, respec-
tively. Interestingly, the scleroderma patients experiencing
a worsening in the alveolar score at one-year follow-up
were found to have lower thymosin b4l e v e l s .W eh a v e
hypothesized that the release of high amounts of thymo-
sin b4 in the extracellular compartment during lung
T: thymosin; s: sulfoxide; N%: BALF neutrophil percentage count; CD4/CD8: ratio between BALF
CD4 cells and BALF CD8 cells; CD4%: BALF CD4 percentage count; DLCO: carbon monoxide
diffusing capacity; BALF: bronchoalveolar lavage fluid. 
r= + 0.36
p= 0.013
r= -0.43
p= 0.007
r= +0.31
p= 0.04
r= -0.39
p= 0.009
Figure 2 Positive correlation between thymosin b4 sulfoxide and BALF neutrophil percentage count and between thymosin b10 and
BALF CD4 percentage count. Negative correlation between thymosin b4 sulfoxide and BALF CD4/CD8 ratio and between thymosin b10 and DLCO.
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sin b4 may exert a cyto-protective effect during lung
injury being BALF lower levels associated to interstitial
lung disease progression. Further studies in a larger number
of SSc patients are needed to validate BALF b-thymosins as
biomarkers of lung involvement. Moreover, it would be
clinically helpful to investigate if b-thymosin plasma levels
correlate to BALF levels
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